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Abstract
Background: Tripartite Motif Containing 11 (TRIM11), a member of TRIM proteins, is overexpressed in high-grade
gliomas and plays an oncogenic function in glioma biology. However, little is known about the role of TRIM11 in
lung cancer.
Methods: We analyzed TRIM11 mRNA expression in lung cancer tissues and adjacent non-neoplastic tissues by
real-time PCR. We then explored the function of TRIM11 in lung cancer cells by small interfering RNA-mediated
downregulation of this protein followed by analyses of cell proliferation, migration and invasion.
Results: TRIM11 was highly expressed in lung cancer tissues and lung cancer cell lines. The higher expression of
TRIM11 was correlated with the poorer prognosis of patients. Suppressing of TRIM11 expression in lung cancer
cells with higher expression of TRIM11 (A549 and NCI-H446 cells) significantly reduced cell growth, motility and
invasiveness. We further demonstrated that knockdown of TRIM11 affected the expression of cell proliferation-related
proteins (Cyclin D1 and PCNA), and epithelial-mesenchymal transformation-related proteins (VEGF, MMP-2, MMP-9,
Twist1, Snail and E-cadherin). The activity of ERK and PI3K/AKT was also suppressed in TRIM11 knocked down cells.
Further experiments in lung cells with lower expression of TRIM11 (NCI-H460 and NCI-H1975 cells) with AKT inhibitor
suggested that TRIM11 may promote cell motility and invasiveness through AKT pathway.
Conclusions: Our results indicate that TRIM11 acts as an oncogene in lung cancer through promoting cell growth,
migration and invasion. Our findings may have important implication for the detection and treatment of lung cancer.
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Background
Lung cancer is the most frequently diagnosed malignancy.
It is the leading cause of cancer death with over 1 million
death annually in the world [1]. Non-small cell lung car-
cinoma (NSCLC) is the most frequently occurring of lung
cancer and accounts for approximately 85 % of lung can-
cer [1]. NSCLC includes adenocarcinoma (ADC), squa-
mous cell carcinoma (SCC), large cell carcinoma (LCC)
and others [2]. Despite recent advances in diagnosis and
treatment, the prognosis of lung cancer is still poor [3].
Therefore, a better understanding of which pathways or
proteins are active in lung tumor progression will contrib-
ute to the development of early detection and targeted
therapy for lung cancer [4–6].
Tripartite Motif Containing (TRIM) proteins are charac-
terized by the presence of tripartite motif, which is com-
posed of a RING domain, 1 or 2 B-box motifs and a
coiled-coil region (RBCC) [7]. Most members of TRIM
proteins, including TRIM11 could be defined as E3 ubi-
quitin ligases. Besides RBCC domain, TRIM11 contains a
PRY domain and a SPRY domain. TRIM11 is thought to
destabilize Humanin (24-amino-acid neuroprotective pep-
tide) [8], activator-recruited cofactor 105-kDa component
(ARC105) [9], PAX6 (a member of the paired-box family
of transcription factors) [10] and PHOX2B (a paired box
homeodomain transcription factor) [11]. Earlier studies on
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TRIM11 have revealed its roles in nervous system func-
tion and development [8, 10, 11]. Recently, TRIM11 ex-
pression was found elevated in high-grade gliomas and it
may exert an oncogenic function in glioma biology [12].
Other members of TRIM proteins, such as TRIM25 [13]
and TRIM59 [14], have been reported to be upregulated
in lung cancer, while TRIM16 [15] and TRIM31 [16] were
found decreased in NSCLC. However, few investigation
has been performed to test the expression and functions
of TRIM11 in lung cancer.
In this study, TRIM11 expression was frequently higher
in lung cancer tissues than corresponding adjacent non-
neoplastic tissues. We investigated whether TRIM11 regu-
lated cell proliferation and metastasis of lung cancer. Our
study showed that TRIM11 promoted cell migration and
invasion by activating the PI3K/AKT signal pathway. Our




120 patients with lung cancer undergoing surgical resec-
tion at Department of Thoracic Surgery, Northern Jiangsu
People’s Hospital (Yangzhou, China) were enrolled in this
study. The age of enrolled patients was between 34 and 72
(median 56) years. 63 participants (52.5 %) were male and
57 (47.5 %) were female. Primary lung cancer tissues were
collected from all enrolled patients, while adjacent non-
cancerous tissues were obtained from 35 patients of the
enrolled patients. The follow-up lasted 5 years. The study
was reviewed and approved by Research Ethic Committee
in Northern Jiangsu People’s Hospital (Yangzhou, China).
Written informed consent was obtained from all patients.
RNA isolation and real-time PCR
Total RNA from tissues and cells was extracted using Tri-
zol (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. The residual DNA was removed
by treating with DNase I (Roche, Indianapolis, IN, USA).
Real-time PCR was used to evaluate TRIM11 mRNA
levels. Total RNA (2 μg) was reverse-transcribed to cDNA
with M-MLV Reverse Transcriptase Kit (Thermo Fisher,
Rockford, IL, USA). The resulted cDNA was used for real-
time PCR with SYBR Green qPCR Master Mix (Thermo
Fisher) on ABI 7300 system (Applied Biosystem, Foster
City, CA, USA) following manufacturer’s instruction. The
relative TRIM11 mRNA levels were calculated by
normalization to GAPDH mRNA levels. The PCR primers
were as follows: TRIM11 forward, 5’- CACCTAAGCTG
CACAGTTCC-3’; TRIM11 reverse, 5’- GGCTGCCTCCT
AATTCTTCC -3’; GAPDH forward, 5’-CACCCACTCCT
CCACCTTTG-3’; GAPDH reverse, 5’- CCACCACCCTG
TTGCTGTAG -3’.
Western blotting
Frozen tissue sample (about 0.1 g) was ground into
powder using liquid nitrogen. Protein was extracted
from frozen tissue powder and cultured cells by using
RIPA lysis buffer (JRDUN Biotech., Shanghai, China)
with fresh-added proteinase inhibitor cocktail (Sigma,
St. Louis, MO, USA) on ice for 15 min and centrifuged
at 12,000 rpm for 20 min. Protein concentrations were
determined using a bicinchoninic acid kit (Thermo
Fisher). For Western blotting analysis, lysates (30 μg/
well) were subjected to SDS-PAGE and transferred
onto nitrocellulose filter membranes. After blocking in
5 % skim milk at room temperature for 30 min, the
membranes were incubated with primary antibodies
overnight at 4 °C. Horseradish peroxidase conjugated
secondary antibodies were subsequently used. Signals
were detected using chemiluminescenct substrate (ECL;
Bio-Rad, Richmond, CA, USA) and exposed to X-ray film.
The results were scanned and analyzed using Image J soft-
ware (http://rsb.info.nih.gov/ij/, Bethesda, MD, USA).
Antibodies against anti-TRIM11, proliferating cell nu-
clear antigen (PCNA), vascular endothelial growth
factor (VEGF), matrix metalloproteinase (MMP)-2,
MMP-9, Twist1, PI3K and p-PI3K were from Abcam
(Cambridge, MA, USA). Antibodies against CyclinD1,
Snail, E-cadherin (CDH1), AKT, p-AKT, ERK, p-ERK and
GAPDH Cell Signaling Technology (Danvers, MA, USA).
Cell culture
Human lung adenocarcinoma cell lines A549, NCI-
H1975 and PC-9, human large cell lung carcinoma cell
lines NCI-H460, small cell lung cancer cell line NCI-
H446 and human embryo lung fibroblasts MRC-5 were
obtained from cell bank of Shanghai Biology Institute,
Chinese Academy of Science (Shanghai, China). The
lung cancer cell lines were cultured in RPMI 1640
medium (Invitrogen; Carlsbad, CA, USA). MRC-5 cells
were maintained in Eagle’s Minimum Essential Medium
(EMEM). Both medium were supplemented with 10 %
fetal bovine serum (FBS; Gibco, Los Angeles, CA, USA),
1 % penicillin/streptomycin and 2 mM L-glutamine. All
cell lines were cultured in at 37 °C, 5 % CO2.
Knockdown of TRIM11 expression by small interference
RNA (siRNA) transfection
Three siRNA targeting human TRIM11 mRNA (siRNA1,
5’- CAGAAGUUGUGCCUAUGGA -3’; siRNA2, 5’- GCU
AUUACAAUUCCUCGGA -3’; and siRNA3, 5’- CUAUU
CAUCUUUCCCGAGA -3’) and a non-specific control
siRNA sequence (NC) were synthesized by Genepharma
(Shanghai, China) and transfected into A549 and NCI-
H446 cells with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) per the manufacture’s instruction. Real-time
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PCR and Western blot analysis were performed at 48 h
after transfection to assess knockdown efficiency.
Construction of TRIM11 lentivirus
Full-length human TRIM11 was cloned into the
pLVX-AcGFP1-C1 (Clontech, Palo Alto, CA, USA).
Lentiviral constructs of pLVX-AcGFP1-C1 empty vec-
tor or pLVX-AcGFP1-C1-TRIM11 were cotransfected
with viral packaging plasmids (psPAX2 and pMD2.G)
into 293 T cells with Lipofectamine 2000. At 48 h post
transfection, viral supernatant was collected to in-
fected NCI-H460 and NCI-1975 cells.
Cell proliferation assay
A proliferation assay was carried out using Cell Counting
Kit-8 (CCK-8, Dojindo Laboratories, Japan) according
to the manufacturer’s protocol [17]. Briefly, 2000 cells/
well were seeded into 96-well plates and transfected
with indicated siRNA. The cells were cultured for 0, 24,
48 and 72 h, then 10 μL CCK-8 reagent was added to
each well and the cells were incubated at 37 °C for 1 h.
The absorbance was recorded at 450 nm with a micro-
plate reader (Bio-Rad).
Transwell migration and invasion assays
Cell migration was assayed using Transwell with 8-μm-
pore filters (Corning; New York, NY, USA) as previ-
ously described [5]. Cells were treated with the desired
siRNA or expression virus. At 24 h after treatment,
cells were trypsinized, resuspended in serum-free
RPMI1640 medium and placed in the upper chamber
(5 × 104 cells/well) and treated with MK-2206 (Merck,
Germany) or DMSO (Sigma). Then RPMI 1640 medium
supplemented with 10 % FBS was added to the lower
chamber. Non-migrating cells in the upper chamber were
completely removed with a cotton swab 24 h later. Mi-
grated cells were stained with 0.5 % crystal violet and
counted in five random fields.
Cell invasion assays were also performed in the same
condition expect that the upper chamber was pre-coated
with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA).
Statistical analysis
All values are expressed as the mean ± SD. Statistical
analysis was tested using Graphpad Prism (Graphpad
Software, San Diego, CA, USA). For comparison between
Fig. 1 TRIM11 expression in lung cancer tissues a Analysis of TRIM11 expression in lung cancer tissues (n = 488) and normal tissues (n = 58) in
TCGA dataset. b TRIM11 mRNA levels in lung cancer and normal tissues from patients admitted to Department of Thoracic Surgery, Northern
Jiangsu People’s Hospital were determined by real-time PCR, with GAPDH as a control. c Kaplan-Meier survival analysis of 120 lung cancer patients
revealed the correlation between TRIM11 expression and prognosis
Table 1 Correlation of TRIM11 expression with patients’ features
Variables All cases TRIM11 mRNA
Low (n = 60) High (n = 60) P value
Age at surgery
< 55 48 25 23 0.8523
> =55 72 35 37
Gender
Male 63 31 32 1.0000
Female 57 29 28
Tumor type
SCC 52 31 21 0.1112
ADC 34 14 20
LCC 13 8 5
SCLC 21 7 14
Tumor size
< 5 cm 49 32 17 0.0090**
> =5 cm 71 28 43
TNM stage
I + II 55 36 19 0.0032**
III 65 24 41
Lymphnode metastasis
Absent 66 41 25 0.0057**
Present 54 19 35
Abbreviations: SCC squamous cell carcinoma, ADC adenocarcinoma, LCC large
cell carcinoma, SCLC small cell lung cancer
**P < 0.01
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groups, statistical differences were tested with one-way
analysis of variance (ANOVA), followed by a Sidak’s test
for multiple comparisons. Fisher’s exact test was carried
out to evaluate the relationship between TRIM11 mRNA
expression and clinicopathological features. Kaplan-Meier
survival curves were generated and compared by log-rank
analysis. P < 0.05 was considered significantly different.
Results
TRIM11 was highly expressed in lung cancer tissue
We re-analyzed TRIM11 expression on lung cancer co-
hort from The Cancer Genome Atlas project (TCGA,
https://tcga-data.nci.nih.gov/tcga/), including 58 normal
tissue samples and 488 tumor tissue samples. The results
showed that TRIM11 was highly expressed in tumor tis-
sues compared with normal tissues (Fig. 1a, P < 0.0001).
We then detected TRIM11 mRNA levels in lung cancer
(n = 120) and adjacent normal tissues (n = 35) by quantita-
tive real-time PCR. As shown in Fig. 1b, TRIM11 expres-
sion was significantly higher in lung cancer tissues than
that in normal tissues (P < 0.0001).
Then, according to the TRIM11 expression in tumor
tissues, the 120 lung cancer patients were classified into
two groups: TRIM11 higher group (n = 60) and lower
group (n = 60). Then, the association between TRRM11
expression and patients’ features was analyzed by Fish-
er’s exact test. As shown in Table 1, TRIM11 expression
was significantly correlated with tumor size, TNM stage
and lymph node metastasis. While, no correlation was
observed between TRIM11 expression level and age,
gender or tumor type. Kaplan-Meier analysis showed
that the overall survival time of patients with higher
TRIM11 expression (median survival time: 27 months)
was significantly shorter than those with lower TRIM11
expression (median survival time: 54 months, Fig. 1c, P
< 0.01). Our data demonstrated that TRIM11 was over-
expressed in lung cancer tissues and its expression was
closely related with poor survival of patients with lung
cancer.
TRIM11 mRNA expression was inhibited in cells
transfected with the TRIM11 siRNAs
TRIM11 mRNA expression was determined in 5 lung
cancer cell lines (A549, NCI-H446, NCI-H1975, NCI-
H460 and PC-9) and 1 human embryo lung fibroblast
cell line (MRC-5). As shown in Fig. 2a, TRIM11 mRNA
level was higher in most lung cancer cell lines than in
MRC-5 cells. We observed similar results in the protein
levels of TRIM11 (Fig. 2b).
In order to understand the functional relevance of
TRIM11 expression in lung cancer progression, TRIM11
knock-down cell lines were generated by siRNA trans-
fection. We selected two target cell lines, A549 and
NCI-H446, which showed high levels of TRIM11
Fig. 2 TRIM11 was highly expressed in lung cancer cells and its expression was suppressed by TRIM11 siRNA transfection. a Real-time PCR analysis
for the TRIM11 mRNA expression level in 5 lung cancer cell lines (A549, NCI-H446, NCI-H1975, NCI-H460 and PC-9) and 1 human embryo lung
fibroblast cell line (MRC-5). **P < 0.01 and ***P < 0.001 versus MRC-5 cells. b TRIM11 protein expression was determined by Western blot. Quantification
(right panel) based on at least 3 independent experiments was made by normalizing against GAPDH levels. **P < 0.01 and ***P < 0.001 versus MRC-5
cells. c Real-time PCR analysis showed the efficiency of TRIM11 knockdown in A549 and NCI-H446 cells. WT: wild-type cells. NC: control
siRNA-transfected cells. siRNA1, 2 and 3: TRIM11 siRNA1, 2 or 3-transfected cells. ***P < 0.001 versus NC. d The protein levels of TRIM11 were
determined by Western blot and GAPDH was used as an internal control. Quantification (right panel) was shown. ***P < 0.001 versus NC
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expression. As shown in Fig. 2c, control scrambled siRNA
(NC) had no effects on TRIM11 mRNA expression
compared with wild-type (WT) cells. TRIM11 siRNAs
(siRNA1, siRNA2 and siRNA3) significantly inhibited
TRIM11 mRNA expression compared to cells transfected
with NC in both cell lines. siRNA3 had the best inhibition
effect on TRIM11 mRNA expression. Western blot ana-
lysis was performed to confirm that TRIM11 protein ex-
pression was efficiently inhibited by siRNA3 transfection
in both cell lines (Fig. 2d). Therefore, siRNA3 was used in
all the subsequent experiments.
Inhibition of TRIM11 expression decreased cell
proliferation
CCK-8 assay was performed to determine whether
TRIM11 plays a role in the growth of lung cancer cells.
Cell growth of A549, NCI-H446 (Fig. 3a and b), NCI-
H460 and NCI-H1975 (Additional file 1: Figure S1) cells
was obviously repressed at 48 h and 72 h after TRIM11
expression was inhibited by siRNA3 transfection. On the
contrary, cell growth of two lung cancer cell lines with
low levels of TRIM11 expression (NCI-H460 and NCI-
H1975 cells) was significantly increased by TRIM11
overexpression (Additional file 1: Figure S2).
The protein levels of proliferation regulation proteins,
PCNA and Cyclin D1, were evaluated by Western blot.
The levels of PCNA and Cyclin D1 were reduced in
TRIM11 knockdown cells (Fig. 3c and d). These results
suggested that inhibition of TRIM11 expression inhib-
ited cell proliferation in lung cancer cells.
Suppressing of TRIM11 expression inhibited the motility
and invasiveness of lung cancer cells
The ability of cancer cells to undergo migration and inva-
sion allows them to spread with the tissues and
metastasize to distant organs [18]. To investigate the func-
tion of TRIM11 in the metastasis, the effects of TRIM11
on the migrated and invasive ability of lung cancer cells
were assessed by Transwell assay. As shown in Fig. 4a and
b, silencing of TRIM11 in A549 and NCI-H446 cells
caused a significant reduction in cell migration and cell
invasion.
Moreover, epithelial-mesenchymal transformation (EMT)
is critical for metastasis of cancer cells [19]. We then
detected the protein levels of metastasis and EMT re-
lated proteins by Western blot (Fig 4c and d). The pro-
tein levels of VEGF, MMP-2, MMP-9, Snail and Twist1
were significantly down-regulated in A549 and NCI-H446
Fig. 3 Knockdown of TRIM11 reduced the proliferation of lung cancer cells. a, b CCK-8 assay results of A549 and NCI- H446 cells at 0 h, 24 h,
48 h and 72 h after TRIM11 expression was inhibited by siRNA3 transfection. c, d Expression of PCNA and Cyclin D1 was evaluated by Western
blot. Quantification (bottom panel) based on at least 3 independent experiments was shown. ***P < 0.001 versus NC
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cells with TRIM11 knockdown, while the main factor of
EMT, E-cadherin (CDH1) was significantly increased in
TRIM11 knockdown cells. These data suggested an inhibi-
tory role of TRIM11 on EMTand lung cancer metastasis.
Silencing of TRIM11 repressed the activation of AKT
pathway in lung cancer cells
Extracellular signal-regulated kinases (ERKs) [20] and
PI3K/AKT [21] pathways, which are key signaling path-
ways involved in cell growth and migration, are frequently
overactivated in tumor cells. Knockdown of TRIM11 in
glioblastoma multiforme cells suppressed the activity of
ERK pathway, while had no effects on PI3K/AKT activity
[12]. To explore the effect of TRIM11 on PI3K/AKT and
ERK pathways in lung cancer cells, phosphorylation of
PI3K, AKT and ERK was determined by Western blot. As
shown in Fig. 5, transfection of TRIM11 siRNA in lung
cancer cells significantly reduced the phosphorylation of
PI3K, AKT and ERK.
To further confirm the involvement of PI3K/AKT
signaling, an AKT inhibitor (MK-2206) was used. NCI-
H460 and NCI-H1975 cells, which showed low levels of
Fig. 4 Knockdown of TRIM11 inhibited the motility and invasiveness of lung cancer cells. a Migration assay was performed on wild-type (WT) cells,
cells transfected with control siRNA (NC) and cells transfected with TRIM11 siRNA3 (siRNA3). Representative images (left panel) and quantitative results
(right panel) were shown. b Invasion assay was carried out. c, d Expression of metastasis-related proteins was evaluated by Western blot. e *P < 0.05,
**P < 0.01 and ***P < 0.001 versus NC
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TRIM11 expression, was overexpressed with TRIM11
and treated with MK-2206. Cell migration and invasion
was then evaluated by Transwell assays (Fig. 6). Cell
migration and invasion of lung cells was significantly
enhanced by TRIM11 overexpression, but suppressed by
MK-2206 treatment. More importantly, the promotion
effects of TRIM11 overexpression on cell migration and
invasion were weakened by MK-2206 exposure. These
data indicated that TRIM11 may promote cell migration
and invasion partially by activating PI3K/AKT pathway.
Discussion
The altered expression of TRIM proteins has been re-
ported in a variety of human cancers, including lung
cancer [13–16]. Di, K. et al. demostrated diagnostic and
prognostic value of TRIM11 in gliomas [12]. However,
the expression and function of TRIM11 in lung cancer
has been poorly characterized. Here, by analyzing on-
line available dataset (Fig. 1a), we found that TRIM11
mRNA was elevated in lung cancer tissues, which was
confirmed by real-time PCR analysis on 120 patients
admitted at Department of Thoracic Surgery, Northern
Jiangsu People’s Hospital (Fig. 1b). Fisher’s exact tests
(Table 1) and Kaplan-Meier survival curves (Fig. 1c)
demonstrated the strong association between TRIM11
expression and tumor size, TNM stage, lymph node
metastasis, as well as overall survival of lung cancer pa-
tients. Thus, TRIM11 may serve as a useful diagnosis
and prognosis marker for lung cancer although further
in-depth clinical study is needed.
Then we investigated the functions of TRIM11 in lung
cancer. The in vitro experiments demonstrated that in-
hibition of TRIM11 expression in lung cancer cells with
higher expression of TRIM11 (A549 and NCI-H446
cells) suppressed cell growth (Fig. 3), migration (Fig. 4a)
and invasion (Fig. 4b). On the contrary, ectopic expres-
sion of TRIM11 in in lung cells with lower expression of
TRIM11 (NCI-H460 and NCI-H1975 cells) had inverse
effects (Additional file 1: Figure S2 and Fig. 6). These
data suggest that TRIM11 may play an oncogenic role
by promoting the proliferation, migration and invasion
of lung cancer cells. Our results of in vitro experiments
were consistent to our clinical observation that high
expression of TRIM11 associated with lymph node
Fig. 5 Knockdown of TRIM11 inhibited the activation of PI3K/AKT and ERK pathways in lung cancer cells. Total protein and phosphorylation of
PI3K, AKT and ERK was evaluated by western blot in A549 a and NCI-H446 cells b. **P < 0.01 and ***P < 0.001 versus NC
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metastasis and tumor size. Furthermore, cancer cells
gain migratory and invasive properties through the
process of EMT [22]. Functional loss of E-cadherin has
been considered as a key event during the process of
EMT [23]. Twist1 and Snail can repress the expression
of E-cadherin, and has been regarded as EMT-inducers
[24]. VEGF [25] and MMP-2/9 [26] are well-known to
play an important role in tumor metastasis. Here, knock-
down of TRIM11 decreased the expression of metastasis
(VEGF, MMP-2 and MMP-9) and EMT-related proteins
(Twist1 and Snail), while increased the expression of E-
cadherin. Our data suggested that TRIM11 siRNA may
inhibit lung cell invasion via suppressing EMT.
Further, in addition to cellular phenotype, we tried to
investigate the molecular mechanism through which
TRIM11 works as an oncogene in lung cancer. ERK and
PI3K/AKT pathways can promote cell growth and metas-
tasis [27, 28]. Both ERK [20] and PI3K/AKT [21] pathways
are frequently over-activated in various tumor types. Di,
K. et al. found that knockdown of TRIM11 in glioblastoma
multiforme cells had no effects on PI3K/AKT activity, but
suppressed ERK activity [12]. In the current study, we
found a notable decrease of ERK and PI3K/AKT activation
(Fig. 5) in TRIM11 knocked down lung cancer cells. The
discrepancy of data and the previous study [12] could be
due to the different cell types used. Accumulating evi-
dence points to the important role of cell motility and
invasion in cancer progression and metastasis [29]. Phos-
phorylation levels of AKT was found to be associated with
the invasion and metastasis of NSCLC [30]. In the present
study, TRIM11 overexpression can promote the PI3K/
AKT pathway (Additional file 1: Figure S2). The promo-
tion effects of TRIM11 overexpression on cell migration
Fig. 6 Ectopic expression of TRIM11 impaired the effects of AKT inhibitor on the migration and invasion of lung cancer cells. a, b NCI-H460 and
NCI-1975 cells were infected with control virus (Vector) or TRIM11 virus, and migration and invasion assay were performed in the present of either
DMSO or AKT inhibitor (MK-2206, 2 μM). MK-2206 was dissolved in DMSO as a 10 mM stock solution. Thus, 0.02 % DMSO was used as negative
control. ***P < 0.001 versus Vector + DMSO; ###P < 0.001 versus TRIM11 + DMSO; $$$P < 0.001 versus Vector + MK-2206
Fig. 7 Schematic representation of the biologic role of TRIM11 in lung
cancer. TRIM11 may act as an oncogene lung cancer by promoting cell
proliferation, migration and invasion. TRIM11 may modulate
PI3K/AKT pathway
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and invasion were significantly weakened by the exposure
of AKT inhibitor, MK-2206 (Fig. 6), which suggested that
TRIM11 might promote cell migration and invasion par-
tially by activating AKT pathway. Thus, we speculated that
elevated TRIM11 will facilitate the development and inva-
sive property of lung cancer through AKT pathways.
However, the mechanisms are needed to be further eluci-
dated in detail.
Conclusions
In summary, increased expression of TRIM11 was noted
in lung cancer tissues. TRIM11 functions as an oncogene
in lung cancer through promoting cell proliferation, mi-
gration and invasion. Moreover, we demonstrated that
TRIM11 may modulate PI3K/AKT pathway (Fig. 7). Con-
sidering that TRIM11 expression level was associated with
patients’ overall survival, TRIM11 may be a new potential
target in lung cancer treatment.
Additional file
Additional file 1: Figure S1. Knockdown of TRIM11 reduced the
proliferation of NCI-H460 and NCI-H1975 cells. Figure S2. Effects of
TRIM11 overexpression on cell proliferation. (DOCX 884 kb)
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